Turnstone Biologics Corp

Turnstone Biologics Corp(TSBX)财务数据

$0.355

+0.005 (+1.43%)收盘时

TSBX 盈利能力与利润率

Evaluating the bottom line, Turnstone Biologics Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -126.71%, provide a clear picture of how effectively TSBX converts its operational activities into shareholder value.

TSBX 同业对比

In the context of the broader market, TSBX competes directly with industry leaders such as ADVB and TRAW. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TSBX's gross margin of N/A stands against ADVB's N/A and TRAW's N/A. Such benchmarking helps identify whether Turnstone Biologics Corp is trading at a premium or discount relative to its financial performance.

Financials

FY2025Q2
0.00
Total Revenue
FY2025Q2
YoY:
-83.41%
-3.66M
Operating Profit
FY2025Q2
YoY:
-74.23%
-5.49M
Net Income after Tax
FY2025Q2
YoY:
-73.91%
-0.24
EPS - Diluted
FY2025Q2
YoY:
-73.15%
-4.30M
Free Cash Flow
FY2023Q4
YoY:
0.00%
100.00
Gross Profit Margin - %
FY2023Q4
YoY:
+235.69%
-349.12
FCF Margin - %
FY2023Q4
YoY:
+579.63%
-285.92
Net Margin - %

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始